abstract |
A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism n n n n n n n n n n wherein X is a nitrogen atom or CH; R 1 is -A 11 -A 12 ; A 11 is a single bond or a C1-6 alkylene group; A 12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R 2 is -A 21 -A 22 ; A 21 is a single bond or a C1-6 alkylene group; A 22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R 3 is a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R 4 is a hydrogen atom or a C1-6 alkoxy group; R 5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R 6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R 7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group. |